Learn more about the innovative light-based therapy for meibomian gland dysfunction (MGD).
Alma offers the benefits of Intense Pulsed Light (IPL) with OptiClear - the specialized light-based solution for the treatment of Meibomian Gland Dysfunction (MGD).
MGD is the leading cause of evaporative dry eye (Dry Eye Disease - DED), which affects millions of people around the world and can lead to chronic eye discomfort and inflammation.
Standard treatments such as anti-inflammatory drops, oral antibiotics and warm compresses provide only temporary relief or are completely ineffective.
MGD is associated with inflammation of the eyelids as well as several symptoms that can severely limit quality of life for patients. These include dryness, itching, red eyes, fatigue and, most importantly, blurred vision in many cases.
Alma offers a breakthrough Dry Eye solution that targets the cause, not just the symptoms. OptiClear is a gentle, non-invasive yet highly effective treatment that stimulates the meibomian glands while relieving vascular inflammation, providing long-term relief from meibomian gland dysfunction.
Alma's IPL technology, OptiClear, uses light energy in a precise narrow-band spectrum in a targeted therapeutic range because clinical research has shown that the 550-650 nm wavelength range alleviates the symptoms of MGD and provides effective, long-term relief.